Chemoradiotherapy for Treatment of Esophageal Cancer in Japan: Current Status and Perspectives

Por Shitara, Kohei, Muro, Kei
Publicado em 2009

Was the Unexpected Result a Response to Reintroduction of Effective Chemotherapy?

Por Shitara, Kohei, Muro, Kei
Publicado em 2009

No benefit from ramucirumab in first-line chemotherapy?

Por Mitani, Seiichiro, Muro, Kei
Publicado no Transl Gastroenterol Hepatol (2017)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy

Por Kadowaki, Shigenori, Yatabe, Yasushi, Nitta, Sohei, Ito, Yuichi, Muro, Kei
Publicado em 2014

Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy

Por Mitani, Seiichiro, Kadowaki, Shigenori, Taniguchi, Hiroya, Muto, Hisanori, Muro, Kei
Publicado no Case Rep Oncol (2016)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based...

Por Mishima, Hideyuki, Oba, Koji, Sakamoto, Junichi, Muro, Kei, Yoshino, Takayuki, Hyodo, Ichinosuke, Maehara, Yoshihiko
Publicado em 2012

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

Por Kadowaki, Shigenori, Yatabe, Yasushi, Hirakawa, Hitoshi, Komori, Azusa, Kondoh, Chihiro, Hasegawa, Yasuhisa, Muro, Kei
Publicado em 2013

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications

Por Shitara, Kohei, Yokota, Tomoya, Takahari, Daisuke, Shibata, Takashi, Sato, Yozo, Tajika, Masahiro, Ura, Takashi, Muro, Kei
Publicado em 2010

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

Por Boku, Narikazu, Muro, Kei, Machida, Nozomu, Hashigaki, Satoshi, Kimura, Nobuyuki, Suzuki, Mie, Lechuga, Mariajose, Miyata, Yoshinori
Publicado em 2013

Trastuzumab for a Patient With Heavily Pretreated Gastric Cancer Plus Massive Ascites and Ovarian Metastasis

Por Shitara, Kohei, Yatabe, Yasushi, Yokota, Tomoya, Takahari, Daisuke, Shibata, Takashi, Ura, Takashi, Satoh, Yozo, Kodera, Yasuhiro, Muro, Kei
Publicado em 2012

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study

Por Kondoh, Chihiro, Shitara, Kohei, Nomura, Motoo, Takahari, Daisuke, Ura, Takashi, Tachibana, Hiroyuki, Tomita, Natsuo, Kodaira, Takeshi, Muro, Kei
Publicado no BMC Palliat Care (2015)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer

Por Sasaki, Yasutsuna, Nishina, Tomohiro, Yasui, Hirofumi, Goto, Masahiro, Muro, Kei, Tsuji, Akihito, Koizumi, Wasaburo, Toh, Yasushi, Hara, Takuo, Miyata, Yoshinori
Publicado no Cancer Sci (2014)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11

Por Taniguchi, Hiroya, Yamazaki, Kentaro, Yoshino, Takayuki, Muro, Kei, Yatabe, Yasushi, Watanabe, Toshiaki, Ebi, Hiromichi, Ochiai, Atsushi, Baba, Eishi, Tsuchihara, Katsuya
Publicado no Cancer Sci (2015)

Comprehensive Registry of Esophageal Cancer in Japan, 2010

Por Tachimori, Yuji, Ozawa, Soji, Numasaki, Hodaka, Ishihara, Ryu, Matsubara, Hisahiro, Muro, Kei, Oyama, Tsuneo, Toh, Yasushi, Udagawa, Harushi, Uno, Takashi
Publicado no Esophagus (2017)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature

Por Honda, Kazunori, Ando, Masashi, Sugiyama, Keiji, Mitani, Seiichiro, Masuishi, Toshiki, Narita, Yukiya, Taniguchi, Hiroya, Kadowaki, Shigenori, Ura, Takashi, Muro, Kei
Publicado no Case Rep Oncol (2017)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study

Por Kato, Ken, Ura, Takashi, Koizumi, Wasaburo, Iwasa, Satoru, Katada, Chikatoshi, Azuma, Mizutomo, Ishikura, Satoshi, Nakao, Yoshinori, Onuma, Hiroshi, Muro, Kei
Publicado no Cancer Sci (2018)

Comprehensive Registry of Esophageal Cancer in Japan, 2011

Por Tachimori, Yuji, Ozawa, Soji, Numasaki, Hodaka, Ishihara, Ryu, Matsubara, Hisahiro, Muro, Kei, Oyama, Tsuneo, Toh, Yasushi, Udagawa, Harushi, Uno, Takashi
Publicado no Esophagus (2018)

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors

Por Kojima, Takashi, Yamazaki, Kentaro, Kato, Ken, Muro, Kei, Hara, Hiroki, Chin, Keisho, Goddemeier, Thomas, Kuffel, Stefan, Watanabe, Morihiro, Doi, Toshihiko
Publicado no Cancer Sci (2018)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese...

Por Doi, Toshihiko, Muro, Kei, Yoshino, Takayuki, Fuse, Nozomu, Ura, Takashi, Takahari, Daisuke, Feng, Hwa-ping, Shimamoto, Takashi, Noguchi, Kazuo, Ohtsu, Atsushi
Publicado em 2013

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer

Por Doi, Toshihiko, Boku, Narikazu, Kato, Ken, Komatsu, Yoshito, Yamaguchi, Kensei, Muro, Kei, Hamamoto, Yasuo, Sato, Atsushi, Koizumi, Wasaburo, Mizunuma, Nobuyuki, Takiuchi, Hiroya
Publicado em 2010